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Objective: In this study, we aim to evaluate trends in the condition of fetuses and
neonates with hemolytic disease at the time of first intrauterine transfusion (IUT)
and at birth, in relation to routine first‐trimester antibody screening, referral guide-
lines, and centralization of fetal therapy.
Method: We conducted a 30‐year cohort study including all women and fetuses
treated with IUT for red cell alloimmunization at the Dutch national referral center
for fetal therapy.
Results: Six hundred forty‐five fetuses received 1852 transfusions between 1 Jan-
uary 1987 and 31 December 2016. After the introduction of routine first‐trimester
antibody screening, the hydrops rate declined from 39% to 15% (OR 0.284, 95% CI,
0.19‐0.42, P < 0.001). In the last time cohort, only one fetus presented with severe
hydrops (OR 0.482, 95% CI, 0.38‐0.62, P < 0.001). Infants are born less often
<32 weeks (OR 0.572, 95% CI, 0.39‐0.83, P = 0.004) and with higher neonatal hemo-
globin (P < 0.001). Neonatal hemoglobin was positively independently associated with
gestational age at birth, fetal hemoglobin, and additional intraperitoneal transfusion at
last IUT.
Conclusion: Severe alloimmune hydrops, a formerly often lethal condition, has prac-
tically disappeared, most likely as a result of the introduction of routine early alloan-
tibody screening, use of national guidelines, and pooling of expertise in national
reference laboratories and a referral center for fetal therapy.1 | INTRODUCTION
Hemolytic disease of the fetus and newborn (HDFN) is a serious com-
plication in pregnancy that has long been a major cause of perinatal
mortality. The disease is caused by maternal alloimmunization to fetal
red blood cell antigens, mostly concerning D, followed by K, c, and E.1
The maternal antibodies may cross the placenta and cause fetal hemo-
lysis and anemia, which, if untreated, may lead to fetal heart failure,
hydrops, and death.- - - - - - - - - - - - - - - - - - - - - - - - - - -
the Creative Commons Attribution
ed, the use is non‐commercial and
by John Wiley & Sons LtdIn the 1980s, important progress in the treatment of fetuses with
severe HDFN was made by the introduction of intravascular intra-
uterine transfusion (IUT), now the cornerstone in prenatal manage-
ment.2 However, survival of especially severely hydropic fetuses
remained significantly lower than that of anemic fetuses without
hydrops.3 Severe hydrops is furthermore associated with
neurodevelopmental impairment on the long term.4 Preventing
hydrops is therefore of utmost importance to improve both survival
and long‐term outcome.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
‐NonCommercial‐NoDerivs License, which permits use and distribution in any
no modifications or adaptations are made.
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What's already known about this topic?
• Severe alloimmune hydrops is associated with impaired
outcome on both the short term and the long term.
What does this study add?
944 ZWIERS ET AL.In the first 3 years after the introduction of intravascular IUT in
the Netherlands (1987‐1989), the majority of cases (55%) presented
with hydrops.5 A recent study from our group showed that the inci-
dence of fetal alloimmune hydrops has declined to approximately
13%.6
In this study, we aimed to evaluate trends in the condition of
fetuses and newborns with hemolytic disease at the time of first IUT
and at birth and discuss possible contributing factors.• With routine early alloantibody screening, national
guidelines, and pooling of expertise in national
reference laboratories and a referral center for fetal
therapy, severe alloimmune hydrops has almost
disappeared.
• Survival of hydrops cases no longer differs from
hemolytic disease of the fetus and newborn cases
without hydrops.
• Children treated with intrauterine transfusions are now
in better condition at birth.2 | METHODS
2.1 | Study design, setting, and study population
We conducted a retrospective cohort study including all patients with
red cell alloimmunization requiring IUT in the LeidenUniversityMedical
Center (LUMC) from January 1987 until January 2017. The LUMC
serves as the Dutch national referral center for fetal therapy since
1965. In the Netherlands, the annual live born number was 187 000
in 1987 and 173 000 in 2016 (with a maximum of 206 000 in 2000).7
The prevalence of a clinically relevant alloantibody (father positive for
the antigen) at first‐trimester screening was 0.14% to 0.33% in 2016.8
Patient data, IUT details, and information on pregnancy outcome of
these patients were collected from our electronic prospectively filled
Rhesus database. Cases were excluded if fetal or neonatal death
occurred from causes other than red cell immunization. Diagnostic fetal
blood samplings not followed by IUT, owing to adequate pretransfusion
fetal hemoglobin, were excluded. If the diagnostic fetal blood sampling
confirmed fetal anemia, but the following transfusion failed due to
technical difficulties or complications, the procedure was not excluded.
Suspected severe fetal anemia requiring IUT was defined as (1) a
peak systolic velocity in the fetal middle cerebral artery (MCA) of 1.5
multiples of the median for gestational age, detected by Doppler mea-
surement, and/or (2) the presence of other signs of anemia at ultra-
sound examination (cardiomegaly, ascites, hydrops), or (3) amniotic
fluid delta optical density measurements reaching the upper part of
the Liley zone II or zone III (only in the early years of this study).
2.2 | Prevention, screening, diagnostics, and
treatment
As a primary preventive measure, anti‐D immunoglobulin (RhIg) is
administered to all D‐negative women, carrying a D‐positive child, at
30 weeks' gestation (since 1998) and after birth (since 1969).1 RhIg
prophylaxis has nowadays reached a coverage of approximately
100% in the Netherlands.9
To prevent non‐D immunizations, blood transfusions adminis-
tered to women of reproductive age (<45 y) are K‐ (since 2004), c‐,
and E‐matched in the Netherlands (since 2011).10 The order of imple-
mentation of these and other preventive measures for red cell immu-
nization in the Netherlands is summarized in Table S1.
Despite these preventive measures, alloimmunization may still
occur. Since the late 1960s, D‐negative women are routinely screened
for the presence of alloantibodies at week 32 of pregnancy. This
screening was brought forward to 30 weeks in 1998 and again for-
ward to 27 weeks in 2011. From 1998 onwards, all pregnant women(D‐negative and D‐positive) are routinely screened for antibodies in
the first trimester. Since 2011, the 27 weeks' screening was further-
more broadened to include c‐negative women.11
If screened positive, the antigen status of the fetus is first
assessed by testing the paternal zygosity or by cell‐free DNA testing
in maternal plasma (available for D, c/C, E, and K). If the fetus is
assumed or determined to be antigen‐positive, antibody titers and
antibody‐dependent cell‐mediated cytotoxicity (ADCC) are measured
every 2 weeks, to assess the risk of fetal hemolysis. All laboratory tests
are performed at Sanquin Blood Supply in Amsterdam or the Special
Institute for Blood Group Investigation in Groningen, the two national
referral laboratories.11,12
In case of a high risk of severe hemolysis, indicated by serological
testing or abnormal ultrasound findings, national obstetric guidelines
advise the patient to be referred to the LUMC. The current screening
and prevention protocol in the Netherlands is summarized in a recent
review of de Haas et al and in a national obstetric guideline.1,12 Patients
with D antibodies are to be referred to the LUMCwhen titers grossly rise
above 1:16 or when the ADCC is higher than 50% (>1:16 and >30% for
other Rh antibodies and 1:2 and 30% for anti‐K). The management of
pregnancies complicated by HDFN in our center consists of weekly
monitoring with MCA Doppler until anemia is suspected and interven-
tion is needed, and information is described in more detail previously.6,132.3 | Data collection and outcome definitions
Data on maternal characteristics, primary antibody type, treatment
details, the severity of fetal hemolytic disease (fetal Hb and presence
of hydrops at first IUT), and perinatal outcome were collected.
In order to identify changes over time, all pregnancies were divided
into time groups of 6 years each, based on the year of first IUT (1987‐
1992, 1993‐1998, 1999‐2004, 2005‐2010, and 2011‐2016).
ZWIERS ET AL. 945Hydrops was classified as mild, if a distinct rim of ascites in the
absence or presence of pericardial effusion was seen, whereas abun-
dant ascites, in the absence or presence of pericardial and pleural effu-
sion and skin edema, was considered as severe hydrops.3
Primary outcome was the presence of hydrops (total, mild, and
severe) at the time of first IUT. Furthermore, we assessed the fetal
(Z)Hb concentration at first IUT, which is the number of standard
deviations of fetal Hb from the mean for gestational age (1
SD = 1 g/dL deviation).14 Other outcome measures were as follows:
perinatal survival, defined as surviving the first month of life or
surviving hospitalization (when hospitalized >1 mo after birth),
neonatal Hb, and the proportion of neonates requiring postnatal
exchange transfusion(s).
Perinatal survival in consecutive time cohorts was assessed for all
fetuses and for those with or without alloimmune hydrops.2.4 | Ethical considerations
Only the caregivers knew the identity of their patients, and study data
were analyzed anonymously. Therefore, the medical ethics committee
of the LUMC approved this research (C15.094) and decided, according
to the Medical Research Involving Human Subjects Act (WMO), that
written informed consent was not needed.2.5 | Statistical analysis
As outcome of multiple pregnancies in the same woman might be
interrelated, outcomes were compared using generalized estimating
equations (GEE). Within the GEE, a linear, binary logistic or ordinal
logistic model was used for comparison of estimated means or odds,
respectively. “Time cohort” was used as a continuous predictor to
assess a linear trend in variables over time, rather than an overall dif-
ference in the variable between all time groups.
Before the use of MCA Doppler became the gold standard to set
the indication for IUT around 2000, amniotic fluid delta optical densityTABLE 1 Trends in characteristics of 645 fetuses and 637 pregnancies t
Group
Total
N = 645
1987‐1992
N = 92
1993‐1998
N = 127
Number of IUTs per fetusa 3 [1‐8] 4 [1‐8] 3 [1‐6
Maternal age at first IUT 32 ± 4.5 31 ± 4.2 32 ± 4
Antibody against
D 524 (81) 80 (87) 110 (8
K 83 (13) 7 (8) 11 (9
c 23 (4) 4 (4) 4 (3)
Otherc 15 (2) 1 (1) 2 (2)
GA at first IUT, total 27 + 3 [16‐36] 26 + 4.5 [18‐34] 28 + 1 [1
D immunizations 27 + 5 [16‐36] 26 + 4.5 [18‐34] 28 + 1.5 [1
K immunizations 24 + 2 [16‐35] 21 + 1 [18‐30] 24 [20‐
Data in n (%), mean ± standard deviation, or median [range] if not normally dis
Abbreviation: GA, gestational age; IUT, intrauterine transfusion.
aIf born alive.
bOrdinal logistic generalized estimating equations.
cOther includes E, e, Fya, Jka, and very infrequent antibodies.
dOverall GA over time.measurements were used. These are now known to be less accurate in
predicting moderate to severe anemia,15 and therefore, a sensitivity
analysis was performed for our main outcome analysis, with only
patients treated from 2000 onwards.
Numerical outcomes that were not normally distributed were
transformed to normality (log2 transformation for titers, gestational
age at birth raised to the power of 10).
If important outcomes showed a significant trend over time, we
assessed possible factors associated with this outcome by multivariate
regression using backward selection (Table S2). The choice for inclu-
sion of variables was made on theoretical grounds, and a P value of
>0.1 was used for exclusion of variables.
P values < 0.05 were considered statistically significant.3 | RESULTS
3.1 | Characteristics of the study population
During the 30‐year study period, IUTs were started in 653 fetuses in
645 pregnancies of 551 women. There were eight twin pregnancies
in which both twins were treated with IUT and one more in which
only one fetus required IUTs; the cotwin was D‐negative. Six
singleton pregnancies were excluded because fetal death occurred
from causes other than red cell alloimmunization, described in more
detail previously.16 Two more cases were excluded, as fetal blood
sampling did not reveal fetal anemia, and therefore, no transfusion
was performed.
A total of 645 fetuses remained for analysis in 637 pregnancies of
543 women, receiving a total of 1852 transfusions. In the first time
cohort, fetuses received a median of 4 (range 1‐8) transfusions per
pregnancy, declining to 3 (range 1‐6) in the last time cohort
(P = 0.003); 55% of fetuses treated with IUT were male, and 45%
female. Table 1 shows overall baseline characteristics of these preg-
nancies and trends in characteristics over time.reated with intrauterine transfusion over time
1999‐2004
N = 159
2005‐2010
N = 152
2011‐2016
N = 115 P
] 3 [1‐6] 3 [1‐6] 3 [1‐6] 0.003
.4 32 ± 4.3 32 ± 5.0 32 ± 4.4 0.125
0.074b
7) 126 (80) 113 (74) 95 (83)
) 22 (14) 29 (19) 14 (12)
8 (5) 6 (4) 1 (1)
3 (2) 4 (3) 5 (4)
7‐35] 27 [17‐36] 27 + 4.5 [16‐35] 28 + 2 [16‐35] 0.408d
7‐35] 27 + 0.5 [17‐36] 28 + 6 [16‐35] 28 + 3 [17‐35]
31] 23 + 4 [19‐31] 25 + 4 [18‐35] 26 + 5 [16‐33]
tributed.
946 ZWIERS ET AL.3.2 | Trends in fetal condition at first transfusion
over time
All primary and secondary outcomes are shown in Table 2. In the total
30‐year cohort, at the time of first transfusion, 23% of fetuses showed
signs of hydrops. Hydrops was classified as mild in 14.4% and as
severe in 8.8%. The incidence of hydrops declined significantly over
time, from 41% in the first time cohort (1987‐1992) to 6% in the final
cohort, 2011‐2016 (OR for the presence of hydrops in a later time
cohort 0.556, 95% CI, 0.48‐0.65, P < 0.001). In Figure 1, the propor-
tion of fetuses with hydrops (mild and severe) at first transfusion is
shown over time. Trends in hydrops are shown separately for D and
K immunizations.
The great majority of cases with hydrops were associated with
D, K, or c immunization (97%). Furthermore, we noted one hydrops
case with anti‐e, one with anti‐Fya, and three cases in pregnancies
with antibodies against low frequent red blood cell antigens: one
anti‐Cw and two pregnancies of a woman with “Verdegaal”
alloimmunization.
After the introduction of routine first‐trimester antibody screen-
ing in 1998, the hydrops rate declined significantly, from 39% (up to
1998) to 15% (after 1998, OR 0.284, 95% CI, 0.19‐0.42, P < 0.001);
and the incidence of severe hydrops dropped from 18% to 4% (OR
0.204, 95% CI, 0.11‐0.37, P < 0.001). From 1999 onwards, 21 out of
65 fetuses (32%) with K immunization developed hydrops despite rou-
tine screening, compared with 40/334 (12%) of fetuses affected by
anti‐D (OR 3.508, 95% CI, 1.82‐6.78, P < 0.001). The median gesta-
tional age at first transfusion in K‐affected pregnancies was approxi-
mately 3 weeks earlier than in D immunizations (24 wk and 6 d,
range 16‐35, vs 27 wk and 6 d [16‐36], P < 0.001).
3.3 | Sensitivity analysis
A sensitivity analysis was performed with only cases included treated
from the year 2000 onwards, thus excluding cases in which the deci-
sion for IUT was based on the Liley curve. For this analysis, the time
cohort 1999‐2004 was thus adjusted to 2000‐2004, in which 32/
138 (23%) of cases presented with hydrops at first IUT, significantly
decreasing to 7/115 (6%) (OR for the presence of hydrops in a later
time cohort 0.459, 95% CI, 0.30‐0.70, P < 0.001).
3.4 | Substandard factors in the management of
cases with severe hydrops
To identify possible substandard care factors that might have contrib-
uted to the development of hydrops, charts of the 18 pregnancies that
presented with severe hydrops after the implementation of first‐tri-
mester screening were reviewed.
Eleven of these 18 patients (61%) were treated with IUT within a
day after presentation with severe hydrops at our fetal therapy center,
indicating a possible late referral. Detailed information was not avail-
able for one of these cases, and in two cases, hydrops resulted from
patient delay (first prenatal visit at 20 and 25 wk, despite two previous
affected pregnancies). In a fourth patient, first‐trimester screening was
negative, but severe hydrops was noted at a routine ultrasound
around week 29 and appeared to result from immunization to a notpreviously detected private antigen (Verdegaal). The other seven
patients were subject to protocol violations: delays in respectively
diagnostics (N = 1, blood sent to reference laboratory a month after
positive screening in regional laboratory, father not typed for antigen
against which antibodies were formed) and referral from midwife to
gynecologist despite positive screening (N = 3) and from gynecologist
to our tertiary center although serological risk assessment prescribed
referral (N = 3). Most of these cases (5/7) occurred in the first 3 years
after screening implementation.
Seven out of the 18 cases were timely referred to our center but
still developed severe hydrops. Management factors that may be asso-
ciated with the development of severe hydrops in these cases are as
follows: alternating weekly monitoring with the referring hospital,
not yet optimally skilled in MCA Doppler measurements (four cases
prior to 2000), postponing IUT to optimize birth timing despite amni-
otic fluid delta optical density measurement in “Liley 2c” zone (one
case), and lack of monitoring in the time span awaiting paternal
genotyping in a case with high risk of anemia (ADCC > 80%). No sub-
standard care factors were found in the last patient.3.5 | Trends in survival and neonatal condition over
time
Trends in survival of hydropic and nonhydropic fetuses are shown in
Figure 2 and Table 2. Survival of fetuses without hydrops did not
increase significantly (from 49/54 [91%] in the first 6 years to 101/
105 [96%]) in the last 6 years of the study (OR for survival in a later
time cohort 1.343, 95% CI, 0.89‐2.02, P = 0.158), while survival of
fetuses with hydrops increased from 24/38 (63%) to 6/6 (100%, OR
2.635, 95% CI, 1.37‐5.07, P = 0.004).
The rate of children born very prematurely (before 32‐wk
gestation) declined significantly over time, from 10% of all live‐born
children in the early years to 2% in the last time cohort (OR for very
premature birth in a later time cohort 0.572, 95% CI, 0.39‐0.83,
P = 0.004). Hemoglobin at birth increased significantly over time,
from 9.2 to 12.6 g/dL in the last cohort (P < 0.001). Multivariate
regression was performed to assess factors contributing to this rise;
factors included in this analysis were as follows: number of IUTs
performed, type of antibody (D or K), highest antibody titer, gesta-
tional age at birth, time interval between the last IUT and birth,
transfusion volume (last IUT), additional intraperitoneal transfusion
(last IUT), and pretransfusion fetal hemoglobin at last IUT (Table
S2). With the use of backward selection with a P‐out of 0.1,
gestational age at birth and additional intraperitoneal transfusion
and pretransfusion fetal hemoglobin at last IUT remained and were
positively independently associated with a higher hemoglobin at birth
(Hb 0.187 g/dL higher with every week gestational age, P = 0.010,
Hb 1.3 g/dL higher after intraperitoneal transfusion, P < 0.001, and
Hb 0.62 g/dL higher/point less fetal Hb deficit, and P < 0.001). In
the first years of the study, only 1.1% of patients received an
additional intraperitoneal transfusion, increasing to 37.4% in the last
time cohort.
Currently, only 17% of neonates treated with IUTs receive one or
more exchange transfusions after birth, significantly declining from
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FIGURE 1 Proportion of fetuses with hydrops at time of first
intrauterine transfusion. The proportion of fetuses with alloimmune
hydrops at first intrauterine transfusion, out of all fetuses treated with
intrauterine transfusion, is presented in columns per time cohort. Light
grey means severe hydrops, and dark grey mild hydrops. The lines
reflect the proportion of hydrops cases from fetuses with D (black)
and K (grey) immunization. The introduction of routine first‐trimester
antibody screening is marked by an arrow
FIGURE 2 Survival rates of fetuses with and without hydrops. Lines
reflect the proportion of fetuses treated with intrauterine transfusion
for red cell alloimmunization that survived up to 28 d after birth (or
until hospital discharge if admitted more than 28 d). The lightest grey
is the total cohort, the darker grey is the fetuses without hydrops, and
the darkest line reflect fetuses with mild or severe hydrops at time of
first intrauterine transfusion
948 ZWIERS ET AL.91% in the first cohort (OR for receiving exchange transfusion(s) in a
later time cohort 0.420, 95% CI, 0.36‐.49, P < 0.001).4 | DISCUSSION
This 30‐year cohort study describes factors that contribute to the
gradual and near disappearance of severe alloimmune hydrops, a seri-
ous condition that has negatively influenced fetal survival and long‐
term outcome for decades. The hydrops rate at first IUT keeps declin-
ing since the introduction of routine first‐trimester antibody screeningin 1998. In the last years of this study, less than 1% (1/115) of fetuses
suffered from severe hydrops. Survival of fetuses with and without
hydrops is nowadays almost equal, rising up to or above 95%. Further-
more, fetuses are nowadays born less anemic, which was associated
with additional intraperitoneal transfusion at the last IUT.
Since the introduction of early screening of all pregnant women in
the Netherlands in 1998, the overall hydrops rate in fetuses requiring
IUT declined from 39% to 15%, and the incidence of severe hydrops
reduced more than fourfold, from 18% to 4%. This impressive cur-
rently low incidence of fetal hydrops indicates that fetuses with
HDFN are nowadays identified and treated more timely. We hypoth-
esize that this is mainly due to the implementation of national guide-
lines on management of alloimmunization in pregnancy, covering
screening, laboratory, and clinical monitoring and protocols for timely
referral to the (single) fetal therapy center. The hydrops rates we
found are comparable with those reported in other Western countries
with similar screening programs, which vary between 8% and 16%.17-
23 A study from Belgium also reported severe hydrops in 5% of red
cell–immunized pregnancies.18
Although the hydrops rate in pregnancies complicated by K anti-
bodies has declined impressively since the introduction of routine
first‐trimester antibody screening, the odds of developing hydrops
are still 3.5 times higher than when D immunization and transfusions
are performed approximately 3 weeks earlier in anti‐K cases. To
ensure timely referral to a tertiary center and prevent hydrops, fast
determination of the fetal phenotype in K immunizations is therefore
of uttermost importance.
In developing countries, where routine early antibody screening is
less well organized or lacking,24 the incidence of hydrops at time of
first IUT is remarkably higher. A group from Brazil reported a 34%
hydrops rate in their cohort with mainly D‐immunized pregnancies,
which they contributed to late referral.25 In the largest tertiary referral
center in India, the hydrops rate was 22% in patients with D immuni-
zation requiring IUT between 2011 and 2014. Equal to our findings,
survival was approximately the same for hydropic and nonhydropic
fetuses in this cohort (94% vs. 90%, respectively).26
An additional explanation for the declining incidence of hydrops is
the optimization of diagnostic accuracy to predict severe fetal anemia
over time. The previously used amniotic fluid delta optical density
measurements27 showed limited accuracy in the second pregnancy tri-
mester and in K‐immunized pregnancies15,28 and were gradually
replaced by measuring the peak flow velocity in the MCA by Doppler
ultrasound, which is standard diagnostic care since around 2000.29 To
account for this change in diagnostic management, we performed a
sensitivity analysis with only cases included from 2000 onwards. This
analysis showed a similar result to the main analysis: OR for the pres-
ence of hydrops in a later time cohort 0.459, P < 0.001.
An important finding is that survival of fetuses with hydrops
increased significantly, leading to a similar survival rate in hydropic
and nonhydropic fetuses in recent years. This confirms findings by
others23,26 and is likely partly due to early detection and timely refer-
ral for treatment of fetal anemia. Thus, hydrops, if it occurs at all, is
nowadays usually only mild, which is associated with favorable out-
come. Furthermore, the increase in survival is most profound in cases
with severe hydrops (OR 3.3). A more advanced gestational age at
ZWIERS ET AL. 949birth in later years of the study and/or advancements in prenatal and
especially neonatal management in the past decades may have con-
tributed, as well as a decrease in IUT complications.6 Centralization
of fetal therapy and neonatal care in large volume centers is increas-
ingly important for quality of care.30
Infants born alive after treatment with IUT(s) seem to be in better
neonatal condition nowadays, being less anemic at birth (despite longer
intervals between the last transfusion and birth) and needing less
exchange transfusions. We found that both additional intraperitoneal
transfusion, in adjunct to intravascular transfusion, and more advanced
gestational age at birth were independently associated with higher neo-
natal hemoglobin. As we previously demonstrated, transfusions through
the intrahepatic route gained popularity over the years and are associ-
ated with less procedure‐related complications.6 An additional advan-
tage of this transfusion technique is the possibility to deposit some
extra blood intraperitoneally with the aim to prolong the interval
between transfusions or between the last transfusion and birth.31
We hypothesize that the found reduction in need for exchange
transfusions is mainly caused by the gradual replacement of this inva-
sive procedure by high‐quality intensive phototherapy and the corre-
sponding more restrictive exchange transfusion protocol in 2004.32
This study is conducted in a well‐organized health care system for
alloimmunized pregnant women. The centralization of screening and
treatment gives us great insight and overview in the prevalence of
alloimmunization and the details of intrauterine therapy. A limitation
might be that we were not able to include fetuses with hydrops, but
without IUT. It is therefore possible that some women lost their
fetuses to severe hydrops before referral to our national referral cen-
ter or that labor was induced before performing an IUT. We hypothe-
size that the subsequent underestimation of hydrops deaths will be
greatest in the early years of the study, as this scenario is highly
unlikely in the present screening setting.5 | CONCLUSION
In summary, the incidence of alloimmune fetal hydrops has decreased
importantly over the past decades, most likely as a result of the intro-
duction of early screening for alloantibodies in all pregnancies, use of
national guidelines, and the availability of both national reference lab-
oratories and the pooling of knowledge and expertise in a referral cen-
ter for fetal therapy. In particular, severe alloimmune hydrops, a
formerly often lethal condition, has practically disappeared, not only
leading to improved survival of HDFN but also diminishing risk of
long‐term impairment.
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